Plus Therapeutics, Inc., headquartered in the United States, is a pioneering biotechnology company focused on developing innovative therapies for cancer treatment. Founded in 2016, the company has made significant strides in the field of radiopharmaceuticals, particularly with its lead product, Rhenium-186 NanoLiposome, designed for targeted cancer therapy. With a commitment to advancing treatment options, Plus Therapeutics operates primarily in the oncology sector, leveraging its proprietary technology to enhance the delivery of therapeutic agents. The company has garnered attention for its unique approach to radiotherapy, positioning itself as a leader in the development of next-generation cancer treatments. Notable achievements include successful clinical trials that underscore its potential to improve patient outcomes in challenging cancer types.
How does Plus Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Plus Therapeutics, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Plus Therapeutics, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges. As there are no emissions data or commitments reported, it is unclear how Plus Therapeutics is addressing climate change or its carbon footprint. The lack of information may reflect a broader industry context where many companies are still developing their sustainability strategies. Without specific emissions data or targets, it is essential for Plus Therapeutics to consider implementing robust climate commitments and reduction initiatives to align with industry standards and expectations.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Plus Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.